Castle Biosciences, Inc. products

Our platform combines a unique approach to bring together all the key elements of biologically aware artificial intelligence (AI) to deliver the spatialomics revolution to the clinician and enable individualized, patient-centric decision-making.

Our DecisionDx-CMSeq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue.  The test includes hotspot mutations in the genes BRAF, NRAS and KIT.

Predicting Individual Risk of Recurrence or Metastasis: DecisionDx-Melanoma was designed to address the need for a more accurate predictor of metastatic risk in patients diagnosed with cutaneous (skin) melanoma.

Increased Clarity for Difficult-to-Diagnose Melanocytic Lesions. MyPath Melanoma and DecisionDx DiffDx Melanoma gene expression profile (GEP) tests are designed to provide objective information to aid in the diagnosis and inform management decisions for patients with ambiguous melanocytic lesions.

Predicting Individual Risk of Metastasis: DecisionDx-SCC is now commercially available. DecisionDx-SCC is clinically validated as a significant predictor of metastasis and the strongest predictor of risk compared to traditional clinical and pathological factors. DecisionDx-SCC complements traditional prognostic risk assessment factors, enabling more informed choices about treatment and follow-up care.